<code id='F6548A81D4'></code><style id='F6548A81D4'></style>
    • <acronym id='F6548A81D4'></acronym>
      <center id='F6548A81D4'><center id='F6548A81D4'><tfoot id='F6548A81D4'></tfoot></center><abbr id='F6548A81D4'><dir id='F6548A81D4'><tfoot id='F6548A81D4'></tfoot><noframes id='F6548A81D4'>

    • <optgroup id='F6548A81D4'><strike id='F6548A81D4'><sup id='F6548A81D4'></sup></strike><code id='F6548A81D4'></code></optgroup>
        1. <b id='F6548A81D4'><label id='F6548A81D4'><select id='F6548A81D4'><dt id='F6548A81D4'><span id='F6548A81D4'></span></dt></select></label></b><u id='F6548A81D4'></u>
          <i id='F6548A81D4'><strike id='F6548A81D4'><tt id='F6548A81D4'><pre id='F6548A81D4'></pre></tt></strike></i>

          fashion

          fashion

          author:focus    Page View:73921
          Jennifer Doudna Feng Zhang CRISPR
          CRISPR pioneers Jennifer Doudna and Feng Zhang Illustration: STAT; Photos: AP, Getty

          The revolution started in silence.

          Jennifer Doudna and Emmanuelle Charpentier, now Nobelists, published their first paper announcing a new enzyme for editing DNA in Science in June 2012. It was called CRISPR-Cas9. It wasn’t until January 2013 that the first paper showing the enzyme would work in cells, from Feng Zhang, was published, also in Science. A similar paper from George Church came out at the same time.

          advertisement

          No major media outlet covered the papers. The first story on CRISPR was published that March. But within the ivory tower of academia, it was clear something big was building, as requests for the technology poured in from other researchers and Zhang set up an assembly line in his laboratory to distribute it, with students carrying carefully packed samples to a FedEx office down the street.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Medicare proposal to cover medical devices draws a mixed reaction
          Medicare proposal to cover medical devices draws a mixed reaction

          AdobeThemedicaldeviceindustryissplitonwhetheraproposednewMedicarereimbursementpathwaywilldoanythingt

          read more
          Grail spinoff by Illumina should end disastrous merger attempt
          Grail spinoff by Illumina should end disastrous merger attempt

          AdobeIllumina,theleadingmakerofDNAsequencingmachines,saidSundaythatitwoulddivestGrail,thedeveloperof

          read more
          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more

          Keeping primary care docs in field isn't impossible, says AAFP CEO

          R.ShawnMartin,theCEOoftheAmericanAcademyofFamilyPhysiciansCourtesyAmericanAcademyofFamilyPhysiciansI